Studies have confirmed that the proportion of Th17 cells and the concentration of IL-17 in the bone marrow of patients with newly diagnosed and relapsed AML are significantly increased and that there is no notable distinction between these patients and healthy controls in the CR and disease-free survival (DFS) stages [143]. This evidence concerns the gene IL17A and acute myeloid leukemia.